期刊文献+

对用于包被冠状动脉支架的抗CD34单克隆抗体的生物学指标的质量控制研究 被引量:1

Quality control of anti-CD34 monoclonal antibody used for coating coronary stents
原文传递
导出
摘要 目的:对鼠源抗CD34单克隆抗体的结合活性以及包被在冠状动脉支架上的抗体量和牢固度等技术指标进行评价。方法:采用流式细胞术测定抗CD34单克隆抗体结合KG-1 a细胞的活性;酶联免疫显色方法测定支架上抗体包被量;体外模拟冲刷方法测定支架上抗体牢固度;采用显微镜计数方法测定包被抗CD34抗体支架体外捕获CD34(+)细胞的能力。结果:在抗CD34 M cAb浓度为1μg.mL-1时,细胞平均阳性率为96.34%;支架上抗体含量为50.97 ng.cm-2,而且体外模拟冲刷后支架上抗体含量无显著变化;包被抗CD34单抗的冠状动脉支架捕获细胞数为4万个.cm-2。结论:该方法可用于体外检测抗CD34单克隆抗体包被冠状动脉支架的生物学参数。 Objective:To evaluate the biological parameters of anti-CD34 monoclonal antibody(McAb) used for coating coronary stents.Methods:KG-1a cell binding activity of anti-CD34 McAb was evaluated with flow cytometric methods;Coated quantity of McAb on coronary stents was measured with ELISA;The binding firmness of McAb was evaluated with wash simulation method;The CD34(+) KG-1a cell capture ability of anti-CD34 McAb coated on coronary stents was measured with microscope counting method.Results:When KG-1a cell was treated with 1 μg·mL-1 anti-CD34 McAb,the FITC positive ratio of KG-1a cell was 96.34%;the content of McAb in coronary stent was 50.97 ng·cm^-2;the content of McAb in coronary stent did not change significantly when the wash simulation treatment was applied;the coronary stents coated with anti-CD34 McAb could capture 4×10^4 KG-1a cells each square centimeter.Conclusion:The methods employed above can efficiently evaluate the biological parameters of anti-CD34 McAb used for coating coronary stent.
出处 《药物分析杂志》 CAS CSCD 北大核心 2011年第5期862-866,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 单克隆抗体 支架 CD34 质量控制 monoclonal antibody stent CD34 quality control
  • 相关文献

参考文献10

  • 1Menown I, Lowe R, Penn L Passive stent coatings in the drug - eluting era. J Invasive Cardiol,2005,17 (4) :222.
  • 2Zhou Z, Shi S, Song M, et al. Development of transgenic endothelial progenitor cell - seeded stents. J Biomed Mater Res A ,2009,91 (2) : 623.
  • 3Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997,275:964.
  • 4Ho HH,Chow WH, Ko LY, et al. Successful use of endothelial progenitor cell capture stent for treatment of left main coronary artery disease before non - cardiac surgery for abdominal aortic aneurysm. lnt J Cardiol,2009 ,143( 2 ) :e27.
  • 5Wendel HP, Avci -Adali M, Ziemer G. Endothelial progenitor cell capture stents - hype or hope? lnt J Cardiol,2010,141 ( 1 ) :e20.
  • 6Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34 : the HEAL- ING- FIM (Healthy endothelial accelerated lining inhibits neointi- mal growth - first in man ) registry. J Am Coll Cardiol, 2005,45 : 1574.
  • 7Civin CI, Banquerigo ML, Strauss LC, et al. Antigenic analysis of hematopoiesis. V[. Flow cytometric characterization of My - 10 - positive progenitor cells in normal human bone marrow. Exp Hematol, 1987,15(1) :10.
  • 8Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hemato- poiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG - 1 a cells. J lmmunol, 1984,133(1 ) :157.
  • 9Vaughan WP, Civin CI, Weisenburger DD ,et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glyco protein CD34( MY10). Leukemia, 1988,2(10) :661.
  • 10金旭,冷希岗,刘兰霞,谷海刚,张超,王海,宋存先.新型抗体偶联胶原包被质粒DNA血管支架的研制[J].中国医学科学院学报,2006,28(5):665-669. 被引量:2

二级参考文献16

  • 1Landau C,Lange RA,Hillis LD.Percutaneous transluminal coronary angioplasty.N Engl J Med,1994,330 (14):981-993.
  • 2Topol EJ,Serruys PW.Frontiers in interventional cardiology.Circulation,1998,98 (17):1802-1820.
  • 3van den Brand MJ,Rensing BJ,Morel MA,et al.The effect of completeness of revascularization on event-free survival at one year in the ARTS trial.J Am Coll Cardiol,2002,39(4):559-564.
  • 4El-Omar MM,Dangas G,Iakovou I,et al.Update on in-stent restenosis.Curr Interv Cardiol Rep,2001,3(4):296-305.
  • 5Liistro F,Colombo A.Late acute thrombosis after paclitaxel eluting stent implantation.Heart,2001,86(3):262-264.
  • 6de la Fuente LM,Miano J,Mrad J,et al.Initial results of the Quanam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects.Catheter Cardiovasc Interv,2001,53(4):480-488.
  • 7Wheeler VC,Coutelle C.Nondegradative in vitro labeling of plasmid DNA.Anal Biochem,1995,225 (2):374-376.
  • 8Takahashi A,Palmer-Opolski M,Smith RC,et al.Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent.Gene Ther,2003,10 (17):1471-1478.
  • 9Klugherz BD,Jones PL,Cui XM,et al.Gene delivery from a DNA controlled-release stent in porcine coronary arteries.Nat Biotechnol,2000,18 (11):1181-1184.
  • 10Laitinen M,Hartikainen J,Hiltunen MO,et al.Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty.Hum Gene Ther,2000,11(2):263-270.

共引文献1

同被引文献26

  • 1谭强,邱录贵,李广平,李长虹,孟恒星,杨万松,郑成环,刘洪梅.循环早期内皮祖细胞与外向生长内皮细胞在血管新生中的作用[J].中华高血压杂志,2010,18(7):658-664. 被引量:7
  • 2崔斌,黄岚,宋耀明,李爱民,晋军,覃军,于学军,耿召华.冠心病患者循环内皮祖细胞与相关危险因素及冠状动脉病变的关系[J].中华心血管病杂志,2005,33(9):785-788. 被引量:31
  • 3Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries.Circulation. 2000; 102(24):2945-2951.
  • 4Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292(22): 2727-2734.
  • 5CarterAJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, siroiimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63(4): 617-624.
  • 6Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coil Cardiol. 2006;48(12):2584-2591.
  • 7Nordmann A J, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27(23):2784-2814.
  • 8Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115( 11 ): 1440-1455.
  • 9Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coil Cardiol. 2006;48(1 ): 193-202.
  • 10Kong D, Melo LG, Mangi A,&., et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation. 2004;109(14): 1769-1775.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部